LIDDS AB (publ) announced that the company has closed the on-going R&D collaboration project with Johnson & Johnson Enterprise Innovation Inc. following completion of all activities and delivery of its final report. Following the recent Joint Research Committee, at which the LIDDS team delivered their final report from the collaboration, Johnson & Johnson Enterprise Innovation Inc. communicated its decision to not continue any further development activities at this time. The collaboration was formed in 2021 with the aim to develop an oncology product based on the NanoZolid® technology for an undisclosed indication.